We are live on
!
Find out more
Los Angeles Capital Management Portfolio holdings
AUM
$27.2B
1-Year Est. Return
43.16%
This Fund
S&P 500
This Quarter
Est. Return
-3.12%
1 Year Est. Return
+43.16%
3 Year Est. Return
+177.72%
5 Year Est. Return
+262.7%
10 Year Est. Return
+1,121.27%
AUM
$19.3B
AUM Growth
-$1.05B
(-5.2%)
Cap. Flow
-$77.1M
Cap. Flow
% of AUM
-0.4%
Top 10 Holdings %
Top 10 Hldgs %
26.03%
Holding
1,444
New
138
Increased
405
Reduced
531
Closed
234
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$224M |
| 2 |
Brown-Forman Class B
BF.B
|
+$140M |
| 3 |
UnitedHealth
UNH
|
+$132M |
| 4 |
Monolithic Power Systems
MPWR
|
+$108M |
| 5 |
Oracle
ORCL
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$134M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$122M |
| 3 |
Micron Technology
MU
|
+$122M |
| 4 |
Pfizer
PFE
|
+$120M |
| 5 |
Microsoft
MSFT
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.43% |
| 2 | Healthcare | 14.49% |
| 3 | Financials | 11.62% |
| 4 | Consumer Discretionary | 10.92% |
| 5 | Industrials | 8.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Sanmina
SANM
$11.3B
| $540K | ﹤0.01% |
11,724
-16,848
| -59% | -$785K |
|
902
Insight Enterprises
NSIT
$4.53B
| $539K | ﹤0.01% |
6,546
-4,944
| -43% | -$440K |
|
903
Interparfums
IPAR
$3.75B
| $537K | ﹤0.01% |
7,112
| – | – |
|
|
ABTX
904
DELISTED
Allegiance Bancshares
ABTX
| $537K | ﹤0.01% |
12,890
+2,940
| +30% | +$126K |
|
|
DBD
905
DELISTED
Diebold Nixdorf Incorporated
DBD
| $534K | ﹤0.01% |
+218,685
| New | +$730K |
|
906
Blackrock
BLK
$181B
| $532K | ﹤0.01% |
966
-17,070
| -95% | -$11.2M |
|
907
Chegg
CHGG
$84.7M
| $531K | ﹤0.01% |
+25,206
| New | +$522K |
|
|
SGMO
908
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $531K | ﹤0.01% |
108,343
+61,285
| +130% | +$315K |
|
|
NARI
909
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $529K | ﹤0.01% |
7,282
-7,787
| -52% | -$580K |
|
910
Tredegar Corp
TG
$276M
| $527K | ﹤0.01% |
55,811
| – | – |
|
911
Target Hospitality
TH
$1.64B
| $526K | ﹤0.01% |
41,692
+4,372
| +12% | +$54.7K |
|
912
Omnicell
OMCL
$1.7B
| $525K | ﹤0.01% |
6,037
| – | – |
|
913
OFG Bancorp
OFG
$2.26B
| $524K | ﹤0.01% |
20,863
-980
| -4% | -$26.6K |
|
914
ACI Worldwide
ACIW
$5.27B
| $523K | ﹤0.01% |
25,037
-54,810
| -69% | -$1.36M |
|
915
OSI Systems
OSIS
$3.74B
| $522K | ﹤0.01% |
7,245
-17,345
| -71% | -$1.52M |
|
916
CBIZ
CBZ
$2.96B
| $521K | ﹤0.01% |
12,175
| – | – |
|
917
City Holding Co
CHCO
$2.08B
| $520K | ﹤0.01% |
5,859
-300
| -5% | -$25.7K |
|
918
Seres Therapeutics
MCRB
$45.6M
| $518K | ﹤0.01% |
4,033
-1,238
| -23% | -$127K |
|
919
First Financial Corp
THFF
$978M
| $518K | ﹤0.01% |
11,471
| – | – |
|
|
SPNS
920
DELISTED
Sapiens International
SPNS
| $517K | ﹤0.01% |
26,932
| – | – |
|
|
ABMD
921
DELISTED
Abiomed Inc
ABMD
| $517K | ﹤0.01% |
+2,104
| New | +$568K |
|
922
T-Mobile US
TMUS
$194B
| $516K | ﹤0.01% |
3,845
| – | – |
|
|
PCSB
923
DELISTED
PCSB Financial Corporation
PCSB
| $516K | ﹤0.01% |
28,783
-4,510
| -14% | -$86K |
|
924
Arthur J. Gallagher & Co
AJG
$64.3B
| $515K | ﹤0.01% |
3,006
+1,138
| +61% | +$202K |
|
|
NGMS
925
DELISTED
NeoGames S.A. Ordinary Shares
NGMS
| $514K | ﹤0.01% |
+39,820
| New | +$604K |
|
Similar funds
FDCDDQ
TWC
WP
N
PCH
VAI
Los Angeles Capital Management's Q3 2022 Portfolio in Review
As of Q3 2022, Los Angeles Capital Management held 1,444 positions worth $19.3B, down 5.2% from $20.3B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Los Angeles Capital Management's Q3 2022 filing shows 138 new, 405 increased, 531 reduced and 234 closed positions. Its largest new stake was Neurocrine Biosciences: 791,966 shares worth $84.1M. The largest sale was Alphabet (Google) Class C, an estimated $134M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, down from 32% a quarter earlier, followed by Healthcare and Financials.
- Los Angeles Capital Management's largest Q3 2022 buy was Neurocrine Biosciences: 791,966 shares worth $84.1M.
- Los Angeles Capital Management added most to Broadcom in Q3 2022, an estimated $224M increase.
- Los Angeles Capital Management's biggest Q3 2022 reduction was Alphabet (Google) Class C, cutting an estimated $134M.
- Los Angeles Capital Management fully exited D.R. Horton in Q3 2022, selling an estimated $37.1M.
- Los Angeles Capital Management's ten largest holdings make up 26% of its $19.3B portfolio in Q3 2022.
- Los Angeles Capital Management opened 138 new positions and closed 234 in Q3 2022.
- Los Angeles Capital Management's portfolio value fell 5.2% quarter-over-quarter to $19.3B.
Based on Los Angeles Capital Management's 13F filing for Q3 2022, filed 2 Nov 2022.